Tenax Therapeutics, Inc. (TENX) NASDAQ

6.12

+0.125(+2.09%)

Updated at September 08 12:52PM

Currency In USD

Tenax Therapeutics, Inc.

Address

ONE Copley Parkway

Chapel Hill, NC 27560

United States of America

Phone

919 855 2100

Sector

Healthcare

Industry

Biotechnology

Employees

4

First IPO Date

April 04, 1994

Key Executives

NameTitlePayYear Born
Mr. Christopher T. GiordanoChief Executive Officer, President & Director928,5911975
Dr. Stuart Rich M.D.Chief Medical Officer & Director548,0441950
Mr. Thomas A. McGauleyInterim Chief Financial Officer and Principal Financial Officer & Principal Accounting Officer01973
Dr. Douglas Hay Ph.D.Executive Vice President of Regulatory Affairs0N/A
Mr. Doug RandallChief Business Officer0N/A

Description

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.